Predictors of human papilloma virus (HPV) infection in Italian women

Journal of Medical Virology

Volumn 82, Issue 11, 2010, Pages 1921-1927

  Cercato, M C ^a   Mariani, L ^a   Vocaturo, A ^a   Carrone, A ^b   Terrenato, I ^a   Morano, G ^b   Benevolo, M ^a   Rollo, F ^a   Germelli, C ^a   Paolini, F ^a   Venuti, A ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cervical cancer; Epidemiology; HPV; Questionnaire; Risk factors; Sexual behavior

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CLASSIFICATION; FEMALE; GENETICS; GENOTYPE; HUMAN; ISOLATION AND PURIFICATION; ITALY; MASS SCREENING; MULTIVARIATE ANALYSIS; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PREVALENCE; QUESTIONNAIRE; RISK FACTOR; SEXUAL BEHAVIOR; VIROLOGY; WOMEN'S HEALTH;

ADOLESCENT; ADULT; FEMALE; GENOTYPE; HUMANS; ITALY; MASS SCREENING; MULTIVARIATE ANALYSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; PREVALENCE; QUESTIONNAIRES; RISK FACTORS; SEXUAL BEHAVIOR; WOMEN'S HEALTH; YOUNG ADULT;

EID: 79952117067     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21887     Document Type: Article

References (38)

1. Almonte M, Albero G, Molano M, Carcamo C, García PJ, Pérez G. 2008. Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean. Vaccine 26: L16-L36.
2. American Cancer Society. 2008. Detailed guide: cervical cancer. What are the risk factors for cervical cancer? American Cancer Society Web site. Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_2X_What_are_the_risk_factors_for_cervical_cancer_8.asp (last accessed: November 15, 2009).
3. Ault KA. The Future II Study Group. 2007. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomized clinical trial. Lancet 369: 1861-1868.
4. Bosch FX, de Sanjosé S. 2003. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 31: 3-13.
5. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjosè S, Bruni L, Tortolero-Luna G, Kruger Kjaer S, Muñoz N. 2008. Epidemiology and natural history of human papilloma virus infections and type-specific implications in cervical neoplasia. Vaccine 26: K1-K16.
6. Burchell AN, Winer RL, de Sanjose S, Franco EL. 2006. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 24: S52-S61.
7. Castellsagué X, Schneider A, Kaufmann AM, Bosch FX. 2009. HPV vaccination against cervical cancer in women above 25 years of age: Key considerations and current perspectives. Gynecol Oncol 115: S15-S23.
8. Chan PK, Ho WC, Wong MC, Chang AR, Chor JS, Yu MY. 2009. Epidemiologic risk profile of infection with different groups of human papillomaviruses. J Med Virol 81: 1635-1644.
9. Contoyannis P, Jones AM. 2004. Socio-economic status, health and lifestyle. J Health Econ 23: 965-995.
10. Coutlée F, Gravitt P, Kornegay J, Hankins C, Richardson H, Lapointe N, Voyer H, Franco E. 2002. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol 3: 902-907.
11. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. 2000. Improved amplification of genital human papillomaviruses. J Clin Microbiol 38: 357-361.
12. Harper MD, Paavonen J. 2008. Age for HPV vaccination. Vaccine 26: A7-A11.
13. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet 364: 1757-1765.
14. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, HPV Vaccine Study Group. 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomized control trial. Lancet 367: 1247-1255.
15. Herbert J, Coffin J. 2008. Reducing patient risk for human papillomavirus infection and cervical cancer. J Am Osteopath Assoc 108: 65-70.
16. Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME, Lorincz AT, Burk RD, Morales J, Rodriguez AC, Helgesen K, Alfaro M, Hutchinson M, Balmaceda I, Greenberg M, Schiffman M. 2001. HPV co-factors related to the development of cervical cancer: Results from a population-based study in Costa Rica. Br J Cancer 84: 1219-1226.
17. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S, 2007. Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16, 573 women with cervical cancer and 35, 509 women without cervical cancer from 24 epidemiological studies. Lancet 370: 1609-1621.
18. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A. 2009. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 101: 1612-1623.
19. Lenselink CH, Melchers WJ, Quint WG, Hoebers AM, Hendriks JC, Massuger LF, Bekkers RL. 2008. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One 3: e3743.
20. Muñoz N, Castellsagué X, Berrington de González A, Gissmann L. 2006. Chapter 1: HPV in the etiology of human cancer. Vaccine 24: 1-10.
21. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV Study PATRICIA Group. Greenacre M, 2009. Efficacy of human papillomavirus (HP oncogenic HPV types (PATRICIA): Final analysis of a double-blind randomised study in young women. Lancet 374: 301-314.
22. Schiffman MH, Castle P. 2003. Epidemiologic studies of a necessary causal risk factor: Human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 95: E2.
23. Schlecht NF, Franco EL, Rohan TE, Kjaer SK, Schiffman MH, Moscicki AB, Duffy SW, Marsh International Collaborative Group. 2001. Repeatability of sexual history in longitudinal studies on HPV infection and cervical neoplasia: Determinants of reporting error at follow-up interviews. J Epidemiol Biostat 6: 393-407.
24. Schroder KE, Carey MP, Vanable PA. 2003. Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports. Ann Behav Med 26: 104-123.
25. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D, Dubin G, HPV Study Group for Adult Women. 2009. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 27: 581-587.
26. Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, Lorincz A, Dalby DM, Janjusevic V, Keller JL. 2000. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ 163: 503-508.
27. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A, Survey of HPV in Ontario Women Group. 2003. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 168: 421-425.
28. Shields TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, Ziegler RG, Studentsov YY, McAdams M, Schiffman M. 2004. A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus. Cancer Epidemiol Biomarkers Prev 13: 1574-1582.
29. Smith JS, Melendy A, Rana RK, Pimenta JM. 2008. Age-specific prevalence of infection with human papillomavirus in females: A global review. J Adolesc Health 43: S5-S25. e1-41.
30. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. 2006. HPV-mediated cervical carcinogenesis: Concepts and clinical implications. J Pathol 208: 152-164.
31. Tonon SA, Picconi MA, Zinovich JB, Liotta DJ, Bos PD, Galuppo JA, Alonio LV, Ferreras JA, Teyssié AR. 1999. Human papillomavirus cervical infection and associated risk factors in a region of Argentina with a high incidence of cervical carcinoma. Infect Dis Obstet Gynecol 7: 237-243.
32. Vaccarella S, Franceschi S, Herrero R, Muñoz N, Snijders PJ, Clifford GM, Smith JS, Lazcano-Ponce E, Sukvirach S, Shin HR, de Sanjosé S, Molano M, Matos E, Ferreccio C, Anh PT, Thomas JO, Meijer CJ, IARC HPV Prevalence Surveys Study Group. 2006. Sexual behavior, condom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev 15: 326-333.
33. Venuti A, Badaracco G, Sedati A, Carbini R, Marcante ML. 1994. Determinants of human papillomavirus types 16 and 18 infections in the lower female genital tract in an Italian population. Eur J Gynaecol Oncol 15: 205-210.
34. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6: 271-278.
35. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E. 2006. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459-1466.
36. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
37. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. 2003. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol 157: 218-226. Erratum in: Am J Epidemiol 2003 157: 858.
38. World Health Organization. 2006. Initiative for vaccine research (IVR): human papillomavirus. World Health Organization Web site. Available at: http://www.who.int/vaccine_research/diseases/viral_ cancers/en/index3.html (last accessed: October 22, 2009).